Aug 18, 2021 Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia Learn More
Aug 16, 2021 Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Learn More
Aug 9, 2021 Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update Learn More
Jul 13, 2021 Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc. Learn More